Retinal Vasculitis
8
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Aflibercept
Research Leaders
7 sponsors active, led by Regeneron Pharmaceuticals, Inc.
Related Conditions
Often studied with 12 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (8)
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
Six-months Versus Nine-months ATT for Ocular TB
Intraoperative Application of Fluorescein Sodium Angiography in Vascular Retinopathy
Optical Coherence Tomography (OCT) in Retinal Vasculitis
Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography
Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)
Biological Markers in Retinal Vasculitis
Research Network
Common Treatments
- Aflibercept2
- Antituberculosis Treatment1
- Cyclosporine1
- Interferonalpha2a1
- Intraoperative Fluorescein Angiography1
Active Sponsors
- Regeneron Pharmaceuticals, Inc.2
- National Eye Institute (NEI)1
- L.V. Prasad Eye Institute1
- Jie Zhong1
- Assiut University1
Top Investigators
Tuebingen University Hospital
Oregon Health and Science University
Related Conditions
- Choroiditis1
- Tuberculosis Tb1
- Behcet Syndrome1
- Behcets Disease1
- Uveitis1